ASCO 2025 – Enhertu mounts its first-line charge
Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.
ASCO 2025 – Amgen gets one over on Zai Lab
Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.
ASCO 2025 – Astellas's new Claudin18.2 interest
Evopoint reveals intriguing but opaque first-in-human data for XNW27011.
ASCO 2025 – Astra "looked at" patritumab but passed
As patritumab-dxd's problems mount, Astra's decision to say no to this project looks smart.
ASCO 2025 – Astra seeks a new SERD paradigm
But camizestrant’s use could depend on uptake of monitoring – for now.
ASCO 2025 – J&J takes another prostate cancer shot
The company highlights the safety of its KLK2-targeting T-cell engager pasritamig.
ASCO 2025 – vepdegestrant matches rival degraders
Any hopes of differentiation could come down to side effects.
ASCO 2025 – Dizal goes after the BTK leaders
DZD8586 shows some evidence that it can rescue BTK failures, but its precise role remains unclear.
